Ono Pharmaceutical Co Ltd
TSE:4528

Watchlist Manager
Ono Pharmaceutical Co Ltd Logo
Ono Pharmaceutical Co Ltd
TSE:4528
Watchlist
Price: 1 606 JPY -0.12% Market Closed
Market Cap: 754.2B JPY
Have any thoughts about
Ono Pharmaceutical Co Ltd?
Write Note

Ono Pharmaceutical Co Ltd
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ono Pharmaceutical Co Ltd
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Ono Pharmaceutical Co Ltd
TSE:4528
PP&E Net
ÂĄ107.1B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
6%
Takeda Pharmaceutical Co Ltd
TSE:4502
PP&E Net
ÂĄ1.9T
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
13%
Daiichi Sankyo Co Ltd
TSE:4568
PP&E Net
ÂĄ458.4B
CAGR 3-Years
17%
CAGR 5-Years
14%
CAGR 10-Years
4%
Otsuka Holdings Co Ltd
TSE:4578
PP&E Net
ÂĄ578.8B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
6%
Chugai Pharmaceutical Co Ltd
TSE:4519
PP&E Net
ÂĄ426.4B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
12%
Astellas Pharma Inc
TSE:4503
PP&E Net
ÂĄ315.3B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
5%
No Stocks Found

Ono Pharmaceutical Co Ltd
Glance View

Market Cap
754.4B JPY
Industry
Pharmaceuticals

In the bustling city of Osaka, Japan, Ono Pharmaceutical Co., Ltd. stands as a venerable institution with roots tracing back over three centuries. Origination in 1717 as an apothecary, Ono has evolved into a leading biopharmaceutical company renowned for its pioneering work in immunology. They have a rich history of innovation in drug development, marked by the success of their groundbreaking anti-cancer agent, Opdivo. This is a product of their intensive research and development in the field of immune checkpoint inhibitors, a class of drugs that revolutionizes cancer treatment by bolstering the body's natural defenses to combat malignant cells. Ono’s commitment to R&D, underscored by substantial investment, remains its cornerstone, transforming complex scientific concepts into therapeutic products. The essence of Ono Pharmaceutical’s business model rests on its adeptness at translating scientific excellence into commercial success. They operate within two primary segments: pharmaceutical products and clinical testing-related services. The pharmaceutical segment, the larger of the two, is the engine driving revenue through the development and global distribution of prescription drugs, focusing extensively on treatments in the central nervous system, cancer, and infectious diseases. Ono leverages strategic alliances with global pharmaceutical giants, facilitating broader distribution networks and shared research endeavors, thus amplifying their market presence and financial returns. Their strategy encapsulates a cycle of discovery, development, and commercialization, continually striving to deliver innovative medicinal solutions that enhance the quality of life worldwide.

Intrinsic Value
2 699.78 JPY
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Ono Pharmaceutical Co Ltd's PP&E Net?
PP&E Net
107.1B JPY

Based on the financial report for Sep 30, 2024, Ono Pharmaceutical Co Ltd's PP&E Net amounts to 107.1B JPY.

What is Ono Pharmaceutical Co Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
6%

Over the last year, the PP&E Net growth was 1%. The average annual PP&E Net growth rates for Ono Pharmaceutical Co Ltd have been -2% over the past three years , -1% over the past five years , and 6% over the past ten years .

Back to Top